To include your compound in the COVID-19 Resource Center, submit it here.

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB) receptor proteins.

Fcabs are Fc domains that can

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE